SequelSEC

Stereotaxis, Inc. STXS

Electromedical & Electrotherapeutic Apparatus · CIK 0001289340 · Fiscal year ends 1231

Revenue
$30.07M
Fiscal year ended 2026-06-30
Operating income
-$22.76M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Stereotaxis, Inc. (STXS) reported revenue of $30.07M and net income of -$22.32M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Stereotaxis, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Electromedical & Electrotherapeutic Apparatus.

Income

Stereotaxis, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$30.07M
Cost of revenue$13.36M
Gross profit$16.71M
Operating income-$22.76M
Net income-$22.32M
Research & development$10.04M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$29.42M
General & administrative$18.18M
Selling & marketing$11.24M

Balance

Stereotaxis, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$10.49M
Total assets$55.58M
Current assets$37.99M
Total liabilities$38.10M
Current liabilities$26.80M
Total equity incl. NCI$12.24M
Temporary (mezzanine) equityUnavailable
Inventory$12.52M
Accounts receivable$7.55M
Goodwill$3.76M
Long-term debtUnavailable
Accounts payable$6.87M

Cash flow

Stereotaxis, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$15.29M
Capital expendituresUnavailable
Investing cash flow-$1.29M
Financing cash flow$20.11M
Net change in cash$3.52M
Stock-based compensation$8.67M
Common dividends paid$0
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Stereotaxis, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross margin55.6%
Operating margin-75.7%
FCF marginUnavailable
SBC / revenue28.8%
Current ratio1.42x
Revenue YoY growth-5.5%
Net margin-74.2%
R&D / revenue33.4%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open STXS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2026-06-30

Difference 5234000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.